Study S001112

A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 598 in Subjects With Obesity

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03757130
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 50
Start: 2018-11-26
Primary completion: 2019-12-16
Lead sponsor: Amgen
Conditions: Obesity
Interventions: DRUG:AMG 598; DRUG:Placebo; DRUG:Liraglutide
Results posted: TRUE
Individual participant data sharing: YES

Registered primary outcomes

Number of Participants With Treatment-emergent Adverse Events [207 days]
Number of Participants With TEAEs Due to Laboratory, Electrocardiogram, and Vital Sign Findings [207 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.